Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — JP Morgan Healthcare Conference 2004

45 slides from Neurocrine Biosciences's conference presentation, Jan 14, 2004

  1. Slide 1: Neurocrine Biosciences, Inc. - The Neuro Endocrine Company

    Neurocrine Biosciences, Inc. The Neuro Endocrine Company JP Morgan 1/14/04

  2. Slide 2: Forward-looking risk statement

    This presentation includes early stage clinical data and projections based thereon that involve a number of risks and uncertainties. These risks include the specific risk that the clinical development of the products discussed will not successfully proceed to later stage clinical trials or to eventu

  3. Slide 3: Diversified Development Portfolio

    Diversified Development Portfolio Indiplon Indiplon IR MR APL APL Clinical Multiple Multiple Sclerosis Sclerosis Diabetes Development D2 D2 Agonist Agonist GnRH GnRH Urocortin Urocortin CRF CRF JP Morgan 1/14/04

  4. Slide 4: Research Portfolio

    Research Portfolio The Next Generation of GPCR Small Molecule Drugs CRF1/CRF2 Antagonists Anxiety / Depression / GI GnRH Antagonists EAATs Endometriosis/Fibroids/Prostate Cancer GSK / NBI Neurodegeneration / Schizophrenia NBI Wyeth / NBI 1 New IND per 18 months MCH Obesity / Anxiety 1 backup per yea

  5. Slide 5: NBI Strategic Plan

    NBI Strategic Plan – Research R&D – Development – Commercialization • Co-promote Zoloft………………………………………………….… 2004 • Co-promote Indiplon………………………………………………....2005 • Add in-licensed products………………………………………….…2006 • Expand sales force for other specialty products……………... 2007 • Add internal proprietary

  6. Slide 6: Indiplon for Insomnia

    Indiplon for Insomnia JP Morgan 1/14/04

  7. Slide 7: JP Morgan 1/14/04

    <( SIN DAYBREAK The New York Eimes Science Times Putting a Price on a Good Night's Sleep By ANDREW POLLACK ; : b: de> “4 \ ¥ Carol Costello | You Will Start to pabebimme BusinessWeek |= shortchanging your rest can hurt your health Sleep ins Ullrich Wagner, 1Gak Distance to the Pleiades Insomnia and

  8. Slide 8: Insomnia

    Insomnia Range of Symptoms - Difficulty Initiating Sleep - Waking Often During the Night - Early Morning Awakening - Poor Quality of Sleep/ Non-Restorative Sleep Next-Day Impact JP Morgan 1/14/04

  9. Slide 9: Insomnia Market is Underdeveloped

    Insomnia Market is Underdeveloped 41% Sufferers of Adults 85 MM Diagnosed 26% 22 MM (As Condition or Symptom) Treated(Rx) 10 MM 48% Ambien® & Sonata® Share 47% 5 MM Source: Mattson Jack (Yr. 2005), 4/02; NSF, 2002; PFE SUF Quant, Wirthlin, 2/01; IMS Health, 09/03; SUF Quant, Olitzky Whittle, 08/03 J

  10. Slide 10: Prevalence of Insomnia Compared to Other CNS Disorders

    Prevalence of Insomnia Compared to Other CNS Disorders US Insomnia Sufferers, Millions 85 28 24 4 3 2.5 Sleep Migraine Depression Alzheimer's Schizophrenia Epilepsy Source: Epidemiology Catchment Assessment; Mattson Jack, 4/22/02 JP Morgan 1/14/04

  11. Slide 11: Insomnia Market TRx Growth

    Insomnia Market TRx Growth 167% Growth Since Ambien® Entry 70,000 60,000 TRx (000s) 50,000 40,000 30,000 20,000 10,000 0 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 JP Morgan 1/14/04

  12. Slide 12: Patients Are Dissatisfied with Current Rx Treatment (Ambien)

    Patients Are Dissatisfied with Current Rx Treatment (Ambien®) Percent Agree Responses 0% 5% 10% 15% 20% 25% 30% 35% 40% Still Wake MOTN 37% Still Wake Too Early 30% Rebound Insomnia 24% Feel "Hungover" 22% Unhappy w/ LPS 8% Percent Agree = Sum of “Completely Agree” and “Agree” Responses N=366 Source

  13. Slide 13: Indiplon Differentiation Strategy

    Indiplon Differentiation Strategy Proposed Label — Sleep Initiation — Middle of the Night Dosing — Sleep Maintenance — Long Term Treatment JP Morgan 1/14/04

  14. Slide 14: Rapidly Induces Sleep in the Elderly

    Indiplon Rapidly Induces Sleep in the Elderly Indiplon-IR (Phase II chronic insomnia) 45 Mean +/- SEM 40 40 min. 35 30 Mean LPS (min) p =0.001 25 25 min. 20 p = < 0.001 p = < 0.001 17 min. 18 min. 15 10 5 N = 42 N = 42 N = 42 N = 42 0 Placebo indiplon indiplon indiplon 5 mg 10 mg 20 mg Mean of night

  15. Slide 15: Rapidly Induces Sleep in Adults

    Indiplon Rapidly Induces Sleep in Adults Indiplon–IR (Phase III transient insomnia) 45 40 35 33.06 Mean LPS (min) 30 25 p < 0.0001 20 p < 0.0001 21.17 15 16.83 16.83 10 N=199 N=195 N=188 5 N = 199 N = 195 N N== 188 188 0 Placebo indiplon indiplon 10 mg 20 mg JP Morgan 1/14/04

  16. Slide 16: Indiplon-IR-0115 Residual/Hangover Effects

    Indiplon-IR-0115 (Phase III Transient Insomnia) Residual/Hangover Effects as Assessed by DSST, SCT, VAS DSST SCT VAS 65 66.4 66.0 145 65.3 35 36.3 143.5 35.6 140.6 34.6 60 139.6 135 30 55 125 25 50 45 115 20 40 105 15 35 N=201 N=198 N= 194 N=201 N=198 N=194 N=201 N=198 N= 194 30 95 10 Pla 10 20 Pla

  17. Slide 17: Indiplon Differentiation Strategy

    Indiplon Differentiation Strategy Proposed Label — Sleep Initiation — Middle of the Night Dosing — Sleep Maintenance — Long Term Treatment JP Morgan 1/14/04

  18. Slide 18: Indiplon IR-0209 (MOTN Dosing in Adults) Study Design

    Indiplon – IR–0209 (MOTN Dosing in Adults) Study Design Schematic Randomization Day 14 Day 28 Treatment (Visit 1) (Visit 2) Day 0 (Visit 3) (Visit 4) (Visit 5) NBI-34060 10 mg Screening Placebo Lead-In NBI-34060 20 mg Visit Day –28 to -15 Day –14 to -1 Placebo JP Morgan 1/14/04

  19. Slide 19: IR-0209 Primary Efficacy Endpoint: LSO

    Indiplon – IR–0209 (MOTN Dosing in Adults) Primary Efficacy Endpoint: LSO – Intent-to-Treat Analysis LSO (minutes) Placebo Indiplon 10 mg Indiplon 20 mg Week 4 P=0.0023 P<0.0001 JP Morgan 1/14/04

  20. Slide 20: IR-0209 Weekly Primary Efficacy Endpoint: LSO

    Indiplon – IR–0209 (MOTN Dosing in Adults) Weekly Primary Efficacy Endpoint: LSO – Intent-to-Treat Analysis LSO (minutes) Placebo Indiplon 10 mg Indiplon 20 mg Week 1 P=0.0007 P=0.0003 Week 2 P=0.0071 P=0.0116 Week 3 P=0.0014 P=0.0021 Week 4 P=0.0014 P=0.0002 JP Morgan 1/14/04

  21. Slide 21: IR-0209 Secondary Endpoint: sWASO

    Indiplon – IR–0209 (MOTN Dosing in Adults) Secondary Endpoint: sWASO – Intent-to-Treat Analysis sWASO (minutes) Placebo Indiplon 10 mg Indiplon 20 mg Week 4 P=0.0048 P<0.0001 JP Morgan 1/14/04

  22. Slide 22: IR-0209 Secondary Endpoint: Total Sleep Time

    Indiplon – IR–0209 (MOTN Dosing in Adults) Secondary Endpoint: Total Sleep Time – Intent-to-Treat Analysis sTST (minutes) Placebo Indiplon 10 mg Indiplon 20 mg Week 4 P=0.0099 P<0.0001 JP Morgan 1/14/04

  23. Slide 23: IR-0209 Patient Reported Sleep Quality

    Indiplon – IR–0209 (MOTN Dosing in Adults) Patient Reported Sleep Quality – Intent-to-Treat Analysis Placebo Indiplon 10 mg Indiplon 20 mg Week 4 P=0.0007 P<0.0001 Scale of 1 (Excellent) to (Extremely Poor) Mean Baseline Sleep Quality for all patients = 4.27 JP Morgan 1/14/04

  24. Slide 24: Indiplon Differentiation Strategy

    Indiplon Differentiation Strategy Proposed Label — Sleep Initiation — Middle of the Night Dosing — Sleep Maintenance — Long Term Treatment JP Morgan 1/14/04

  25. Slide 25: MR Improves Sleep Maintenance in the Elderly

    Indiplon-MR Improves Sleep Maintenance in the Elderly Indiplon – MR (Phase II chronic insomnia) 400 p < 0.0001 p < 0.0001 390 p < 0.0001 390.5 min 389.7 min 380 384.4 min (+ 51 min) 370 Mean TST (min) p < 0.02 360 359.6 min 350 340 339.7 min 330 320 310 N = 60 N = 60 N =60 N =60 N = 60 300 Placebo i

  26. Slide 26: Indiplon MR-0221 Phase III Trial Design

    Indiplon – MR-0221 (PIII Adult Sleep Maintenance Insomnia Trial) Objective: To evaluate the efficacy and safety of indiplon MR relative to placebo in adults with sleep maintenance insomnia Design: Phase III Randomized Double-blind, Placebo-controlled, Outpatient, Multi-center Study Population: 3-mon

  27. Slide 27: MR-0221 Primary Endpoint (sTST)

    Indiplon – MR-0221 (PIII Adult Sleep Maintenance Insomnia Trial) Primary Endpoint (sTST – Sleep Maintenance) ITT Analysis Set sTST (min) Placebo Indiplon 30 mg p-value Baseline 323.7 318.7 N/A (3 min) (57 min) Week 1 326.9 377.3 <0.0001 (12 min) (51 min) Week 2 336.3 369.5 0.0006 JP Morgan 1/14/04

  28. Slide 28: MR-0221 Secondary Endpoint (sWASO)

    Indiplon – MR-0221 (PIII Adult Sleep Maintenance Insomnia Trial) Secondary Endpoint (sWASO) ITT Analysis Set sWASO (min) LS Mean Placebo Indiplon 30 mg p-value Baseline 83.7 90.7 N/A Week 1 79.1 52.3 <0.0001 Week 2 73.4 52.1 0.0011 JP Morgan 1/14/04

  29. Slide 29: MR-0221 Daytime Drowsiness and Sleep Quality

    Indiplon – MR-0221 (PIII Adult Sleep Maintenance Insomnia Trial) Patient Reported Daytime Drowsiness and Sleep Quality at Week 2 Placebo Indiplon 30 mg p-value Daytime Drowsiness 3.54 3.63 N.S. Sleep Quality 4.10 3.53 <0.0001 JP Morgan 1/14/04

  30. Slide 30: Indiplon Differentiation Strategy

    Indiplon Differentiation Strategy Proposed Label — Sleep Initiation — Middle of the Night Dosing — Sleep Maintenance — Long Term Treatment JP Morgan 1/14/04

  31. Slide 31: Efficacy Maintained for Long Term Treatment (35 days)

    Indiplon Efficacy Maintained for Long Term Treatment (35 days) Indiplon-IR (Phase III chronic insomnia) Persistence of LPS Effect – no tolerance Mean LPS (min) Day 1-2 Day 15-16 Day 29-30 Placebo 36.9 39.9 40.1 Indiplon 10mg 27.7** 30.4** 29.2** Indiplon 20mg 27.1* 28.7* 24.9** *p<0.05 **p<0.01 JP M

  32. Slide 32: Safety Demonstrated Over One Year of Treatment

    Indiplon Safety Demonstrated Over One Year of Treatment Indiplon-IR (Phase III chronic insomnia) — 211 patients have completed all study visits and LPLV has occurred — Average dose = approx 20/month — Preliminary blinded (to dose) data observations: • Well tolerated • No clinically relevant effects

  33. Slide 33: Summary of Phase III Program

    Indiplon Summary of Phase III Program # of Patients in Program Study Population Type of Study IR MR Primary Insomnia (Adult) Efficacy, Safety, MD OP 700 740 Primary Insomnia (Elderly) Efficacy, Safety, MD OP 358 223 Transient Insomnia (Adult) Efficacy, Safety, SD PSG 593 325 35d Chronic Insomnia (Ad

  34. Slide 34: Small Molecule / Oral GnRH Antagonist

    Small Molecule / Oral GnRH Antagonist JP Morgan 1/14/04

  35. Slide 35: Current World Wide Market Value & Future Market Opportunities

    Current World Wide Market Value & Future Market Opportunities Market Value, Major Brands Significant Unmet Medical 2002 Sales, WW (>$2.6 B) Need in Women’s Health1,2,3 2002 Treated Endometriosis 118 Product Company Sales (GnRHA) ($2.5B) Lupron TAP $876m Symptomatic 1,844 Leuprolide Abbott $172m Leup

  36. Slide 36: Rationale: Anticipated Characteristics of Small Molecule Antagonists

    Rationale: Anticipated Characteristics of Small Molecule Antagonists Peptide Agonists Small Molecule Antagonists — Delayed effect (1 month) — Rapid onset of action — Initial stimulation — Pure antagonism — Delayed recovery — Rapid recovery time — Depot — Oral — On/Off only (menopause) — Dosing possi

  37. Slide 37: NBI-56418: Phase I Single, Multiple-Dose Study

    NBI-56418: Phase I Combined Single, Multiple-Dose: PK, PD, Safety and Tolerability Objectives • Primary – Safety and Tolerability • Secondary – Pharmacokinetics and Pharmacodynamics Design • Randomized, double-blind, placebo Single-dose arm controlled, dose escalating, 1- and 7-day # # # # # # # dos

  38. Slide 38: CRF Receptor Antagonists

    CRF STRESS STRESS CRF AVP Corticotrope Corticotrope Receptor Asn34 Arg35 Arg35 Lys36 Asn34 Lys Met38 Glu39 36 Glu39 38 Met Ile41 Ile41 Ile40 Ile40 ββ-Endorphin -Endorphin ACTH Gln30 Ser33 Gln30 Ser33 Cortex Cortex Adrenal Adrenal Gln29 Ala31 Gln29 Ala31 Leu37 Leu37 Antagonists Glu25 Gln26 Glu25 Gln2

  39. Slide 39: Depression, Anxiety and IBS: GlaxoSmithKline Collaboration

    Depression, Anxiety and IBS GlaxoSmithKline Collaboration • Expected Advantages over Existing Therapies: – Better Efficacy (Efficacy in patients refractory to current therapies) – Faster onset of Efficacy – Superior side-effect profile (No sexual dysfunction) – Lack of Sedation – Opportunity for Com

  40. Slide 40: Altered Peptide Ligands for Multiple Sclerosis

    Development of Antigen Presenting Cell MHC Altered Peptide Ligands TH2 Cells for the APL APL T-Cell Treatment of TH1 T-Cell TH2 Multiple Sclerosis Cytokines JP Morgan 1/14/04

  41. Slide 41: NBI-5788 for Multiple Sclerosis

    NBI-5788 for Multiple Sclerosis Phase I – Single dose safety: 30 patients – Multiple dose safety immune response: 30 patients Phase II a – Safety and Efficacy: 144 patients Phase II b: Enrolling 150 patients at 24 sites in North America JP Morgan 1/14/04

  42. Slide 42: Altered Peptide Ligands for Diabetes

    Development of Antigen Presenting Cell MHC Altered Peptide Ligands TH2 Cells for the APL APL T-Cell Treatment of TH1 T-Cell TH2 Diabetes Cytokines JP Morgan 1/14/04

  43. Slide 43: NBI-6024 Clinical Program

    NBI-6024 Clinical Program Phase I – SD adult safety - UK and RSA, N=20 – completed – MD adult safety - RSA , N=30 – completed – MD adult & adolescent safety - US, N=40 – completed – MD adolescent safety - RSA, N=35 – completed Phase II – Adult/Adolescent Dose Response, Safety and Efficacy, – Placebo

  44. Slide 44: Financial Highlights

    Financial Highlights YTD YTD Dec. 31, 2003 Dec. 31, 2002 Revenues Revenues and and other $ 167.6 million* $ 27.1 million other income income Operating Operating and and other other Expenses Expenses $ 197.9 million $ 121.6 million Net Net loss loss $ (30.3) million $ (94.5) million Cash Cash and and

  45. Slide 45: Neurocrine Biosciences, Inc.

    Neurocrine Biosciences, Inc. JP Morgan 1/14/04

Neurocrine Biosciences — JP Morgan Healthcare Conference 2004 on 6ix